INTRODUCTION
Transforming growth factor-beta (TGF-beta) is a prototypic member of a large family of structurally related pleiotropic cytokines that exhibits a vital role in various biological processes such as regulation of cell proliferation, extra-cellular matrix production, apoptosis, angiogenesis and immune responses (1). Approximately 40 distinct TGFbeta members have been identified and they are generally divided into two subfamilies -the TGF-beta/activin/nodal family and BMP (bone morphogenetic protein)/GDF (growth and differentiation factor)/MIS (Mullerian inhibiting substance) subfamily as defined by sequence similarity and the specific signaling pathway they activate (2-4). The physiological effects of TGF-beta are manifested in a cell and context dependent manner and the cytokine has an important role as an antithetic in cells of different developmental lineages (5).
Improper signaling by TGF-beta has been implicated in a wide variety of human diseases, such as autoimmune disease (6, 7), tumorigenesis (8), and vascular disorders (9, 10). Due to its major role in cellular physiology, the specificity of TGF-beta is tightly regulated. TGF-beta can act as both tumor suppressor and as a significant stimulator of tumor progression, invasion and metastasis (11). As TGF-beta induces extra-cellular matrix accumulation, angiogenesis and immuno-suppression, it is reported to facilitate progression of tumors under certain conditions (12, 13) . Depending on the cell type, TGF-beta is required for the maintenance of genomic stability, induction of replicative senescence and suppression of telomerase (14) , and it appears to be important for prevention of early stage tumorigenesis. The tumor suppressor activity of TGF-beta pathway derives in part from its ability to inhibit growth of epithelial and lymphoid cells from which tumors arise. Recent studies indicate that TGF-beta exhibits pro-oncogenic effects that directly target the tumor itself in addition to indirect effects on the stromal compartment (15) .
TGF-BETA LIGANDS AND RECEPTORS
TGF-betas are synthesized as latent high molecular weight complexes from producer cells and are activated by various mechanisms, including effects of plasmin and thrombospondin (16, 17) . Latent TGF-beta can be activated by fibronectin receptor, alpha(v)-beta6, in squamous carcinoma cells (18) . On the other hand, TGFbeta2 induces matrix metalloproteinases (MMPs) expressions and suppresses tissue matrix metalloproteinase inhibitor (TIMP)-2 expressions that promotes the invasion of U87MG and LN-229 glioma cells in a matrigel invasion TGF-beta ligand binding with TGFbetaRII recruits TGFbetaRI into a tetrameric receptor complex resulting in trans-phosphorylation and activation of TGFbetaRI. After phosphorylation, the activated TGFbetaRI catalyzes phosphorylation of R-Smad, a receptor-regulated Smad. The resulting Smad complex moves into the nucleus and associates with transcriptional co-factors such as certain members of Forkhead box (Fox) family and other families of transcriptional factors). Finally, R-Smad complex binds to specific DNA-binding co-factors in target genes and activates transcription. assay (19). Four isoforms of TGF-betas, TGF-beta1, -beta2, -beta3 and -beta4 are present and TGF-beta1, -beta2 andbeta3 are highly conserved in mammals. The amino acid sequences of all the three isoforms are 70-80% homologous. TGF-beta1 is a 25-kDa nonglycosylated homodimer with nine disulfide bonds and is expressed in endothelial (20), hematopoietic (21-23), and connective tissue cells (24). TGF-beta2 is expressed in epithelial and neuronal cells and TGF-beta3 primarily in mesenchymal cells (25). The TGF-beta ligands share a common set of sequence and structural features. The active form of TGFbeta cytokine is a dimer stabilized by an intra subunit disulfide. Each of the monomers comprises several extended beta strands interlocked by three conserved disulfide bonds that form a "cysteine knot" (26).
TGF-beta receptors are glycoproteins with serine/threonine kinase activity. Three types of TGF-beta receptors have been identified so far in mammalian cells by cell surface cross-linking experiments. They are type I (55 kDa), type II (75 kDa) and type III (200-400 kDa) based on their electrophoretic mobility (27-30). The type I (TbetaRI) and type II (T-betaRII) receptors have a similar domain structure -a relatively short extra-cellular domain, a single trans-membrane region and a long cytoplasmic region which consists almost entirely of kinase domain (31-34). The T-betaRI receptors contain a characteristic SGSGSG sequence known as the GS-domain, immediately N-terminal to the kinase domain that differentiates them from the T-betaRII receptor (35, 36). The T-betaRII receptor shares 30-40% amino acid identity within the kinase domain with other receptors of the TGF, whereas the T-betaRI receptors share 60-90% identity among their kinase domain.
The T-betaRII receptors and activin are able to bind their respective ligands independently, whereas the TbetaRI receptors require co-expression of T-betaRII receptors (37). More than 90% of hereditary non-polypotic colon cancers and 15% of microsatellite stable colon cancers had inactivating mutations in the T-betaRII gene (38). Somatic mutations in TGF-betaR2, the gene that encodes the T-betaRII receptor occurs most frequently in tumors with patient's hereditary non-polyposis colorectal cancer (HNPCC) (39). In these patients, a repeat stretch of adenines in the T-betaRII coding sequence is prone to mutation, owing to germ line defects in their capacity for DNA mismatch repair.
The type III receptor (T-betaRIII) is a transmembrane 853-amino acid proteoglycan with a large extracellular domain containing both heparin sulfate and chondroitin sulfate chains, followed by a trans-membrane segment and a short cytoplasmic region which is rich in serines and threonines (40). The major function of TbetaRIII is to act as a modulator of ligand access to the signaling receptors. Mutations in TGF-beta receptors can cause hereditary hemorrhagic telangiectasia, primary pulmonary hypertension, persistent mullerian duct syndrome, hereditary nonpolyposis colon cancer (HNPCC) and juvenile polyposis syndrome.
SIGNALING THROUGH TGF-BETA RECEPTOR COMPLEX
Active TGF-beta binds to T-betaRI and TbetaRII, which is required for signaling. TGF-beta binds to T-betaRII and results in trans-phosphorylation of T-betaRI in the GS-domain. The phosphorylated T-betaRI becomes active and propagates the signal through phosphorylation of the Smad proteins. Smad-2 and -3 are activated via Cterminal phosphorylation by T-betaRI kinases and form heteromeric complexes with co-Smad, Smad-4 (39, 41-43). The phosphorylation occurs in the last two serine residues at the terminal Ser-Ser-x-Ser motif of R-Smads. Following phosphorylation of R-Smads by T-betaRI receptors, Smad oligomerization is thought to occur. The phosphorylated Cterminal tail of R-Smads interacts specifically with the L3-loop of another smad, which is sufficient to cause their oligomerization (44). Activated R-Smads then recruit coSmads, forming a heterotrimeric complex that translocates to the nucleus and together with a co-activator or corepressor and a DNA-binding co-factor regulate transcription of target genes (Figure 1) (45, 46) .
In the nucleus, activated Smad complexes can directly recognize target genes with several copies of the Smad cognate sequence CAGAC to which they can bind through their Mad homology 1 (MH1)-domains (47) . As most of the Smad responsive promoter elements contain only one copy of this motif, for effective recognition of such genes under physiological conditions, the Smad complex must incorporate additional DNA-binding co-factors that recognize nearby sequences in the target promoter (48) . Nuclear localization signals (NLS) in the MH1-domains of R-Smads play pivotal roles in translocation of Smads into the nucleus, whereas nuclear export signals in the MH2-domains of R-Smads and those in the linker regions of co-Smads are responsible for nuclear export of the complex (49) (50) (51) . TGF-beta displays a high affinity for the ectodomain of the T-betaRII receptors and do not interact with the T-betaRI receptors (25). This adds in the incorporation of the T-betaRI, forming a large ligand receptor complex involving a ligand-dimer and four receptor molecules. The binding occurs at the far ends of the elongated ligand-dimer. This interaction creates certain concave patches which are supposed to be the binding site for the ectodomain of the T-betaRI. Because of its critical role in receptor activation, the GS-region serves an important regulatory domain for TGF-beta -signaling. Thus, T-betaRII is the primary component of ligandbinding, whereas receptor I is its substrate and a downstream component of the signal transduction pathway (52).
SMADS
Smad family members were first identified through genetic screens in flies and worms, and the family quickly grew to eight mammalian counterparts. The term "Smad" is derived from the fusion of Sma in c. elegans and Mads (Mothers against decapentaplegic) in drosophila (53) . Smads are ubiquitously expressed throughout development and in all adult tissues, and many of them are produced from alternatively spliced mRNAs (54) . Most of the effects of TGF-beta are mainly mediated through the TGF-beta receptor/Smad-signaling pathway. Smads are intracellular nuclear effectors of TGF-beta family members, and there are at least nine different Smads whose relative molecular masses range from 42-60 kDa. Ligand-induced activation of TGF-beta family members with intrinsic serine/threonine kinase activity triggers phosphorylation of TGF-beta receptor regulated Smads.
The Smad family can be divided into three distinct subfamilies -receptor regulated smads (R-Smads), common partner Smads (co-Smads), and inhibitory Smads (I-Smads) (55) . Among the R-Smads, Smad-1, Smad-5 and Smad-8 are substrates for the bone morphogenetic protein (BMP) type I receptors and the orphan receptor activin receptor-like kinase 1 (ALK-1), while Smad-2 and Smad-3 are phosphorylated by TGF-beta or the activin type I receptor. The access of Smads to the receptors is restricted by an anchoring protein named SARA (Smad anchor for receptor activation) (56) . R-Smads are bound to SARA, a Smad-2/Smad-3 interacting protein that contains a double zinc finger or FYVE-domain. SARA is anchored to the plasma membrane by phosphatidyl inositol-3-phosphate (PI3P). SARA forms a dimer in cells and anchors two molecules of unphosphorylated Smad-2/Smad-3 and preferentially binds to the MH2-domains of Smad-2 and Smad-3. When activated Smads become dissociated from SARA, then they are available for phosphorylation by the TGF-beta receptors (57) . The co-Smad including Smad-4 and possibly Smad-10 are present in the cytoplasm and lack the ability to bind to or to be phosphorylated by TGF-beta receptors. I-Smads include Smad-6 and Smad-7 with Smad-6 mainly inhibiting BMP-signaling while Smad-7 is more specific to TGF-beta signal transduction. Smad-4 is a key partner of R-Smads proteins and was originally isolated as the product of tumor suppressor gene DPC4 (43) . It recruits transcription co-activators such as CBP/p300 and migration inhibitory factor 1 (MIF1) to R-Smads and stabilizes the interaction between R-Smads and the co-activators (58, 59) . The levels and activity of Smad-4 are affected both by the ubiquitin-proteosome system and by sumoylation (60) (61) (62) (63) . Smad-4 is a shared component in the TGF-beta/activin and BMP-signaling pathways. If the cellular pool of Smad-4 is limited, these two pathways may antagonize each other by competing for Smad-4 (64). Furthermore, TGF-betasignaling is inhibited by lefty, a novel member of the TGFbeta super-family. Lefty inhibits the events that lie downstream from R-Smad phosphorylation, including heterodimerization of R-Smad proteins with Smad4 and nuclear translocation of the R-Smad.Smad4 complex (65).
R-Smads and co-Smads with about 500 amino acid sequences in length contain two conserved structural domains, the N-terminal Mad homology 1 (MH1) and Cterminal MH2-domains which are separated by a prolinerich linker region (66) . The linker-region contains a number of phosphorylation sites crucial for cross-talk with other signaling pathways. A PY-motif, which specifically interacts with E3 ubiquitin ligases, plays a vital role in TGF-beta and BMP pathways. The L3-loop in the MH2 domain of R-Smads determines the specificity of the interaction with the T-betaRI receptors (45) . The crystal structure of MH1-domain is a compact globular fold composed of four α helices, six short -beta strands and five loops. Additionally, the MH1-domain also has a beta hairpin structure made up of 11 amino acids through which MH1 can directly bind to DNA when activated Smads are trans-located to the nucleus (67) . The MH1-domain is highly conserved among R-Smads and co-Smads. The MH1-domain regulates nuclear import and transcription by binding to DNA and interacting with other nuclear proteins (66) . The MH2-domain is highly conserved among all the Smads. Its structure contains several α-helices and loops, which surround a -beta-sandwich (68) . The MH2-domain regulates Smad oligomerization, recognized by T-betaRI receptors and interacts with cytoplasmic adaptors and several transcription factors.
Smad proteins are suggested to be tumor suppressors. Mutations in Smad genes have been reported in various carcinomas. Smad-4 was originally identified as a tumor suppressor gene lost in pancreatic cancers, deleted in pancreatic cancer 4 (DPC4). About 50% of pancreatic cancers and 30% of colorectal cancers are caused by mutations in Smad-4 (69).
I-SMADS
Smads can positively regulate gene expression by recruiting co-activators such as CBP/p300 or negatively by recruiting histone deacetylases (HDACs) or co-repressors such as C-Ski and SnoN, which themselves associate with HDACs (70) . Negative regulation of Smad-signaling occurs through multiple mechanisms including inhibitory Smad-6, one of the I-Smads exerts inhibitory effects on signaling through other mechanisms than by competing with R-Smads for receptor interaction. Smad-6 competes with Smad-4 for heteromeric complex formation with activated Smad-1 and functions as a transcriptional corepressor through interaction with a homeodomain transcription factor HOXC-8. It also associates with TGFbeta activated kinase (TAK) and interferes with BMPinduced p38 activation (76-78).
SKI
SnoN and ski are two closely related members of the family of nuclear oncoproteins that were identified on the basis of homology with V-Ski, the transforming protein of the Sloan-Kettering virus (79, 80) . They play important roles in repressing Smad-mediated transcriptional activation in normal cells. Ski or SnoN antagonizes TGFbeta signaling through direct interactions with the co-Smad, Smad-4 and the R-Smads, Smad-2 or Smad-3 (81, 82) . This results in the inability of the cell to induce growth inhibitory proteins following TGF-beta addition (83) . High levels of Ski or SnoN are associated with many types of human cancer cells (84) (85) (86) (87) . Increased expression of Ski or SnoN causes oncogenic transformation of chicken and quail embryo fibroblasts (88) . The Ski family of protooncogenes uses two separate sequence motifs to interact with the co-Smad, Smad-4 and the R-Smads, Smad-2, Smad-3, Smad-1 or Smad-5 (89, 90). Studies on crystal structure of a Ski fragment bound to Smad-4 indicates that Ski and the R-Smads compete for mutually exclusive binding to Smad-4 leading to the disruption of functional Smad-4/R-Smad complexes (91) . The N-terminal region of C-Ski (16-40 amino acids) is the most important for the interaction with Smad-3 whereas the I-loop of C-Ski is responsible for the interaction with Smad-3. Binding of Ski to Smad-4 plays an essential role in Ski-mediated repression of TGF-beta signaling as well as Ski-mediated transforming activity (92).
PROTEOSOME AND SMAD SIGNALING
The ubiquitin-mediated proteosomal degradation pathway is a conserved cascade involved in the regulation of key cellular processes such as signal transduction, cell cycle progression, transcriptional regulation and endocytosis. The TGF-beta-signaling pathway is tightly regulated by the ubiquitin-proteosomal degradation system. In response to TGF-beta-mediated stimulation, Smads are also targeted for ubiquitination and degradation which ultimately results in termination of TGF-beta signals (Figure 2) (93) .
Smurfs-1 and -2 are HECT type-E3 ubiquitin ligases, containing the N-terminal C2-domain followed by WW-domains and the C-terminal HECT-domain that interact with R-Smads and induce their degradation (94) . The HECT-domain is responsible for the E3 ligase activities of Smurfs as they catalyze the transfer of the ubiquitin moiety to its target substrates. The WW-domains physically interact with the PY-motifs found in most R-and I-Smads. While Smurf-1 contains two WW-domains, Smurf-2 comprises three WW-domains, resulting from a 31-amino acid insertion downstream of the C2-domain (93) . Smurfs induce degradation of R-Smads indirectly through the binding of R-Smads via I-Smads. The ubiquitination of Smad-2 is carried out by UbcH5b/c-E2 ubiquitin conjugating enzymes and Smurf-2-E3 ubiquitin ligase. Smurf-2 interacts with the ligand activated Smad-2 through its WW-domain and decreases the Smad-2 mediated-transcription (95) . Proteosomal degradation of Smad-2 is likely to occur in the nucleus as suggested by preferential interaction of Smurf-2 with the phosphorylated Smad-2. Similar to Smad-2, the action of the ligandactivated Smad-3 is also ultimately terminated by its degradation via the ubiquitin-proteosome pathway. However, in this case, the SCF/Roc-1-E3 ligase complex has been shown to be responsible for triggering the ubiquitination of phosphorylated Smad-3, after which Smad-3 is exported from the nucleus and undergoes proteosomal degradation in the cytoplasm (96) .
The degradation of activated Smad-1 is reported to occur through a complex containing Smad-1, the ornithine decarboxylase antizyme (Az) and the 20S proteosome beta subunit, Hs-N3, which then targets Smad-1 for proteosomal degradation (97, 98) . Ectopic expression of Jab-1 or Jun-activating domain-binding protein 1 mediated ubiquitination and degradation of Smad-4 (99). Smad-7 expression induced by TGF-beta leads to the association of Smad-7 with Smurf-2 in the nucleus and migration of the complex to the cytoplasm where it binds to the T-betaRI complex and induces its degradation (100, 101) . The degradation of T-betaRI can be also mediated by Smurf-1, another member of HECT family of E3 ubiquitin ligases. Similar to Smurf-2, Smurf-1 is brought to ligand activated type I receptor by Smad-7 and mediates the ubiquitination and proteosome exerted degradation of the receptor (102) . Smurfs induce poly-ubiquitination and degradation not only of Smad-7 but also of type I receptors and inhibit TGF-signaling through the down-regulation of the amount of receptors on cell surface. Smad-7 itself is also degraded via the proteosome when targeting the receptor complex for degradation.
Inactivation of the activities of phosphorylated RSmads is crucial for controlling the extent of TGF-beta effects. Interestingly, although dephosphorylation of activated R-Smads by unidentified phosphatases is thought to contribute to the dissociation of the Smad complexes in the nucleus, growing evidence indicates the phosphorylated R-Smads are inactivated at least partially through the irreversible degradation via the ubiquitin-proteosome system. The ubiquitination of Smad-2 is carried out by UbcH5b/c E2 ubiquitin conjugating enzymes and Smurf-2 E3 ubiquitin ligase (103) . Smurf-2 interacts with the ligand activated Smad-2 through its WW-domain and decreases the Smad-2 mediated transcription. Thus, the proteosome activity limits the function of Smad-2 in the TGF-beta signal transduction pathway. Proteosomal degradation of Smad-2 is likely to occur in the nucleus as suggested by the preferential interaction of Smurf-2 with the phosphorylated Smad-2.
Besides activating the Smad pathway, TGF-beta activates other transduction pathways including MAPK (mitogen activated protein kinase) (104), AP-1 (activated protein-1) (105, 106) , TAK-1 (TGF-beta activated kinase-1) (107) , and Jun-D (member of the AP-1 family transcription factors) (108) pathways. The Smad and TAK-1 pathways synergistically trans-activate transcription factor ATF-2 (109). After TGF-beta binds with the TbetaRII, a heteromeric complex with the T-betaRI is formed, activating the T-betaRI serine/threonine kinase which then phosphorylates Smad-3 (R-Smad). Smad-3 forms a heterotrimeric complex with Smad-4 (co-Smad) that trans-locates to the nucleus and binds ATF-2 and synergistically stimulates its trans-activating capacity (109) . From these studies it has been concluded that ATF-2 plays a central role in TGF-beta signaling by acting as a common nuclear target of both Smad and TAK1 pathways.
ROLE OF TGF-BETA IN TUMOR SUPPRESSION AND TUMOR PROGRESSION
TGF-beta plays a biphasic role in cancer. In the earlier stages of carcinogenesis, it is known to act as a tumor suppressor probably by inhibiting the proliferation of non-transformed cells whereas in the later stages it is known to aid tumor progression by eliciting an epithelial to mesenchymal transition (8). TGF-beta receptors are known to act as tumor suppressors at early stages of carcinoma development. In tumor cells, TGF-beta receptors are often down-regulated or the TGF-beta receptor availability at the cell surface is impaired, and these defects are considered to help the cells to escape from the growth inhibitory properties of TGF-beta (110, 111).
TGF-beta1 is reported to induce a rapid and reversible epithelial-mesenchymal transition (EMT) in melanoma cells (112) and in H-Ras transformed mammary epithelial cells in vitro (113). Experimental animals with one inactivating allele of the gene encoding TGF-beta1 show increased susceptibility for developing carcinoma after exposure to carcinogen (114) . Transfection of weakly tumorigenic colon carcinoma cells with antisense TGF-beta inhibited TGF-beta expression dramatically increased the size of tumors formed by these cells in vivo (115) . T-betaRI mutations have been reported in ovarian carcinoma (116, 117) , head and neck carcinoma (118) , lymphoma (119) as well as in breast metastases (120, 121) . Expression of wild type T-betaRII in colon or breast carcinoma cells, which lack a functional T-betaRII allele, has been reported to show the tumor suppressor role of the T-betaRII in these cells (122) . Expression of T-betaRII strongly reduced tumor formation in nude mice by growth inhibition and by suppressing anchorage independence. Several studies on human tumors also indicate that TGF-beta has a vital role in angiogenesis and is suggested to promote angiogenesis by inducing PAI-1 and thereby inhibiting angiostatin (123) .
APOPTOTIC AND CYTOSTATIC ROLE OF TGF-BETA
TGF-beta is a potent inducer of growth inhibition in several cell types. During cancer, a deregulation in the CDK2, CDK4 and CDK6 occurs through the G 1 phase of cell cycle. In G 1 , the activation of CDK4/6 requires association with D-type cyclins whereas CDK2 is activated by cyclin E. One primary event that leads to TGF-beta induced growth arrest is the induction of expression of the CDK inhibitors P 15 INK4B and/or P 21CIP1 . The inhibitor P 21CIP1 interacts with complexes of CDK2 and cyclin A or cyclin E and thereby inhibits CDK2 activity, preventing progression of cycle (124) . The P 15 INK4B of the INK4 family interacts with and inactivates CDK4 and CDK6 by disrupting their catalytic sites and by inhibiting cyclin binding (125) . Induction of P 15INK4B or P 21(WAF1/CIP1) expression in response to TGF-beta is mainly due to Smad mediated transcriptional activation. TGF-beta downregulates c-Myc to deprive cell of growth promoting functions (126) as well as to facilitate the induction of CDKN2B and CDKN1A and therefore has an integrative role in the TGF-beta cytostatic program (125) .
The apoptotic role of TGF-beta varies depending on the cell type. In various cell types, the TGF-beta inducible early response gene (TIEG1), a transcription factor is reported to inhibit proliferation and induce apoptosis in various cell types (127) . Daxx adaptor protein has been proposed to mediate TGF-beta-induced apoptosis through its ability to interact with the T-betaII receptor (128) . The levels of Smads are reported to have an influence on apoptosis. Increase in the levels of Smads-3 or Smad-4 induces apoptosis (129) . Whereas Smad-7 can act either as an effector of TGF-beta induced cell death as reported in prostatic carcinoma cells (130) or can protect against cell death (131).
SUMMARY AND PERSPECTIVES
The TGF-beta receptor signal transduction pathway plays critical roles in many biological processes, including the development and progression of human tumors. Since TGF-beta receptors-mediated signaling pathway is complicated, it requires interaction with many functionally important molecules in either normal cells or tumor cells. Some of the important molecules which interact with TGF-beta receptor-signaling cascade are Smads, BMP, GDF, MIS, TIMP, SARA, CBP/p300, MIF1, ubiquitin ligases and Smurfs, to name a few. Any defect(s) in the molecules can cause the loss or gain of TGF-beta receptor signaling in normal or tumor cells. In some cases the proliferation of normal epithelial and lymphoid cells are strongly inhibited by TGF-beta, which is lost in cancer cells due to defective TGF-beta receptor-signaling. Interestingly enough, the altered TGF-beta receptor-signaling pathway can also stimulate proliferation of some cancer cells. This further suggests the complexity of the TGF-beta receptorsignaling pathway in normal and cancer cells. Thus, future research needs to be directed toward better understanding the function of various components of TGF-beta receptorsignaling pathways and to design approaches to interfere with these pathways -such as antibodies, RNA interference, chemotherapy and gene therapy.
ACKNOWLEDGEMENTS
We apologize to those colleagues whose work was not cited; instead, many of them have been accommodated in referenced review articles. We thank Mary Wall for proof reading of the manuscript. 
